Pictilisib-Induced Resistance Is Mediated through FOXO1-Dependent Activation of Receptor Tyrosine Kinases in Mucinous Colorectal Adenocarcinoma Cells.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
02 Aug 2023
Historique:
received: 07 07 2023
accepted: 25 07 2023
medline: 14 8 2023
pubmed: 12 8 2023
entrez: 12 8 2023
Statut: epublish

Résumé

The phosphatidylinositol (PI3K)/AKT/mTOR axis represents an important therapeutic target to treat human cancers. A well-described downstream target of the PI3K pathway is the forkhead box O (FOXO) transcription factor family. FOXOs have been implicated in many cellular responses, including drug-induced resistance in cancer cells. However, FOXO-dependent acute phase resistance mediated by pictilisib, a potent small molecule PI3K inhibitor (PI3Ki), has not been studied. Here, we report that pictilisib-induced adaptive resistance is regulated by the FOXO-dependent rebound activity of receptor tyrosine kinases (RTKs) in mucinous colorectal adenocarcinoma (MCA) cells. The resistance mediated by PI3K inhibition involves the nuclear localization of FOXO and the altered expression of RTKs, including

Identifiants

pubmed: 37569713
pii: ijms241512331
doi: 10.3390/ijms241512331
pmc: PMC10418489
pii:
doi:

Substances chimiques

2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine 0
Phosphatidylinositol 3-Kinases EC 2.7.1.-
Receptor Protein-Tyrosine Kinases EC 2.7.10.1
Forkhead Transcription Factors 0
Phosphoinositide-3 Kinase Inhibitors 0
Tyrosine 42HK56048U
Proto-Oncogene Proteins c-akt EC 2.7.11.1
Forkhead Box Protein O1 0
FOXO1 protein, human 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : BLRD VA
ID : I01 BX004127
Pays : United States

Références

Mol Endocrinol. 2006 Oct;20(10):2444-55
pubmed: 16709600
Mol Cancer Ther. 2008 Mar;7(3):670-8
pubmed: 18347152
EMBO J. 2017 Apr 13;36(8):995-1010
pubmed: 28279977
Br J Cancer. 2009 Mar 24;100(6):881-7
pubmed: 19259089
Chin J Cancer. 2013 Jul;32(7):376-9
pubmed: 23668928
Cancer. 1976 Apr;37(4):1891-1900
pubmed: 177180
Nat Rev Cancer. 2002 Jul;2(7):489-501
pubmed: 12094235
Nature. 1999 Apr 15;398(6728):630-4
pubmed: 10217147
Oncogene. 2008 Jan 3;27(1):9-19
pubmed: 17599040
Cell. 1999 Mar 19;96(6):857-68
pubmed: 10102273
Carcinogenesis. 2008 Sep;29(9):1837-44
pubmed: 18390843
J Clin Invest. 2006 Sep;116(9):2464-72
pubmed: 16906224
PLoS One. 2017 Jun 22;12(6):e0179510
pubmed: 28640835
Eur J Cancer. 2012 Mar;48(4):501-9
pubmed: 22226571
Lab Invest. 2019 Nov;99(11):1689-1701
pubmed: 31243340
J Biol Chem. 2020 Mar 27;295(13):4265-4276
pubmed: 32075913
Adv Enzyme Regul. 1984;22:27-55
pubmed: 6382953
Mol Cancer. 2010 Sep 26;9:260
pubmed: 20868520
J Biol Chem. 2003 Dec 12;278(50):49795-805
pubmed: 14527951
Oncogene. 2011 Jun 2;30(22):2547-57
pubmed: 21278786
Acta Chir Belg. 2013 Nov-Dec;113(6):385-90
pubmed: 24494463
Nature. 2002 Sep 19;419(6904):316-21
pubmed: 12239572
Semin Cancer Biol. 2019 Dec;59:92-111
pubmed: 31408724
Dev Cell. 2018 Mar 12;44(5):555-565.e3
pubmed: 29533771
Breast Cancer Res. 2018 Sep 5;20(1):109
pubmed: 30185228
Mol Pharmacol. 2010 Nov;78(5):961-70
pubmed: 20736318
Science. 2004 Dec 17;306(5704):2105-8
pubmed: 15604409
Ann Oncol. 2014 Mar;25(3):651-657
pubmed: 24504447
Cancer Res. 2010 Jan 15;70(2):440-6
pubmed: 20068163
Cancer Res. 2009 Nov 1;69(21):8386-94
pubmed: 19826044
Mol Cancer Res. 2017 Apr;15(4):489-497
pubmed: 28096479
Transl Oncogenomics. 2016 Feb 21;7(Suppl 1):33-49
pubmed: 26917948
Mol Cell Biol. 2000 Dec;20(24):9138-48
pubmed: 11094066
Cancer Commun (Lond). 2019 Mar 29;39(1):13
pubmed: 30922401
Cell Mol Life Sci. 2012 Jun;69(11):1813-42
pubmed: 22204021
J Pathol Clin Res. 2014 Nov 05;1(1):3-17
pubmed: 27499889
Nat Rev Genet. 2006 Aug;7(8):606-19
pubmed: 16847462
Cancer Res. 2006 Jan 1;66(1):212-20
pubmed: 16397234
Cancer Cell. 2011 Jan 18;19(1):58-71
pubmed: 21215704

Auteurs

Murali R Kuracha (MR)

Department of Internal Medicine, University of Nebraska Medicine, Omaha, NE 68198, USA.

Venkatesh Govindarajan (V)

Department of Medical Education, Creighton University School of Medicine, Omaha, NE 68178, USA.

Brian W Loggie (BW)

Department of Surgery, Creighton University School of Medicine, Omaha, NE 68124, USA.

Martin Tobi (M)

Research and Development Service, Detroit VAMC, Detroit, MI 48201, USA.

Benita L McVicker (BL)

Department of Internal Medicine, University of Nebraska Medicine, Omaha, NE 68198, USA.
Research Service, Nebraska-Western Iowa Health Care System, Omaha, NE 68105, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH